Toviaz Tablet, Film Coated, Extended Release
Product Images NDC 0069-0242

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 0069-0242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Toviaz 01)

Chemical structure of fesoterodine fumarate, the active ingredient in Toviaz. The diagram shows the molecular arrangement of atoms and bonds in fesoterodine fumarate.*

FDA Label Image

Figure 1 (Toviaz 02)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in the number of micturitions over 12 weeks. The graph compares placebo, Toviaz 4 mg, and Toviaz 8 mg, with the y-axis representing mean change from baseline and the x-axis representing weeks. Toviaz 8 mg shows the greatest reduction, followed by Toviaz 4 mg, and placebo shows the least change.*

FDA Label Image

Figure 2 (Toviaz 03)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' displaying mean change from baseline in urge incontinence episodes over 12 weeks. It compares three groups: Placebo (dotted line), Toviaz 4 mg (dashed line), and Toviaz 8 mg (solid line), showing decreasing episodes over time for both Toviaz doses relative to placebo.*

FDA Label Image

Figure 3 (Toviaz 04)

Line graph titled 'Change in Number of Micturitions per 24 h (Study 2)' showing mean change from baseline in number of micturitions per 24 hours over 12 weeks. The graph compares three groups: Placebo (dotted line), Toviaz 4 mg (dashed line), and Toviaz 8 mg (solid line), with sample sizes around 266-267 each. Both Toviaz groups show a greater decrease in micturitions compared to placebo over time.*

FDA Label Image

Figure 4 (Toviaz 05)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 2)' showing mean change from baseline in urge incontinence episodes over 12 weeks for placebo, Toviaz 4 mg, and Toviaz 8 mg groups. The y-axis represents mean change in episodes per 24 hours, and the x-axis shows time in weeks from 0 to 12. The graph includes three lines with different markers indicating placebo, Toviaz 4 mg, and Toviaz 8 mg groups.*

FDA Label Image

Logo (Toviaz 06)

FDA Label Image

Logo (Toviaz 07)

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Label)

Label for Toviaz 4 mg extended release tablets, containing the active ingredient fesoterodine fumarate. The package contains 30 film-coated oral tablets. The label includes storage instructions (20° to 25°C) and states the product is distributed by Pfizer Labs, a division of Pfizer Inc. The label also shows the NDC 0069-0242-30 and indicates the drug is prescription only.*

FDA Label Image

Principal Display Panel (8 mg Tablet Bottle Label)

Label for Toviaz 8 mg extended release tablets containing fesoterodine fumarate. The film-coated oral tablets are prescription-only and distributed by Pfizer Labs, Division of Pfizer Inc. The label includes storage instructions, quantity (30 tablets), and barcodes, with origin noted as Made in Ireland.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.